Truist Securities Maintains Buy on Verona Pharma, Raises Price Target to $32
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Joon Lee maintains a Buy rating on Verona Pharma (NASDAQ:VRNA) and raises the price target from $28 to $32.
June 07, 2023 | 12:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities analyst Joon Lee maintains a Buy rating on Verona Pharma and raises the price target from $28 to $32.
The raised price target by Truist Securities analyst Joon Lee indicates a positive outlook for Verona Pharma's stock. This news is likely to have a positive short-term impact on the stock price as it reflects increased confidence in the company's potential growth and performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100